07:00 , Jul 12, 1999 |  BC Week In Review  |  Company News

Apex Bioscience, VitaResc deal

VitaResc, an intensive care medicine company, acquired Apex, into which VitaResc merged its U.S. subsidiary. Apex's pyridoxalated hemoglobin polyoxyethylene has completed Phase II testing to treat nitric oxide-induced shock. Apex Bioscience Inc., Research Triangle Park,...
07:00 , Aug 4, 1997 |  BC Week In Review  |  Company News

Apex Bioscience board of directors update

Apex Bioscience Inc., Research Triangle Park, N.C.   Business: Cancer, Autoimmune/Inflammation   Appointed: Julius Krevans, M.D., medical director of international clinical programs at the University of California, San Francisco; and John Zabriskie, Ph.D., chairman and...
08:00 , Mar 24, 1997 |  BC Week In Review  |  Clinical News

PHP pyridoxalated hemoglobin polyoxyethylene data

Apex said that preliminary results from a Phase I/II open-label trial in 18 patients showed that the compound had potential to restore normal hemodynamics and reduce the need for vasopressor drugs. Results were presented at...
08:00 , Mar 24, 1997 |  BioCentury  |  Product Development

Apex takes on the shock in sepsis

Apex takes on the shock in sepsis A hemoglobin derivative is the latest biotech foray toward the industry black hole of sepsis. But Joseph DeAngelo, the co-inventor of the technology, emphasizes that the treatment is...
07:00 , May 8, 1995 |  BC Week In Review  |  Clinical News

PHP: Began Phase I double-blind, placebo-controlled trial in healthy volunteers to determine safety and tolerance of escalating doses

Apex Bioscience Inc. , Research Triangle Park, N.C.   Product: PHP, pyridoxylated hemoglobin polyoxyethylene, a scavenger of nitric oxide   Indication: Acute hypotension mediated by nitric oxide (e.g. septic shock)   Status: Began Phase I...
08:00 , Mar 13, 1995 |  BC Week In Review  |  Company News

Apex Bioscience deal

Apex received exclusive rights outside of Japan to Ajinomoto Co. Inc.'s pyridoxylated hemoglobin polyoxyethylene conjugate (PHP) to treat disorders related to excess nitric oxide. Ajinomoto (Tokyo) transferred its U.S. IND to Apex (Research Triangle Park,...
07:00 , Sep 26, 1994 |  BC Week In Review  |  Company News

Apex Bioscience deal

Apex and Duke University will develop drugs that modulate nitric oxide levels to treat diseases such as shock-induced hypotension, cancer and autoimmune disorders. In return for providing $1 million in funding, Apex received an option...
08:00 , Mar 28, 1994 |  BC Week In Review  |  Clinical News

Apex Bioscience regulatory update

Apex (Research Triangle Park, N.C.) received U.S. patent No. 5,296,466 covering the use of hemoglobin and other iron-containing proteins to treat hypotension induced by septic shock. Apex said that lowering nitric oxide levels with hemoproteins...